BioHarvest Sciences, Inc. · NASDAQ:BHST
BioHarvest Sciences — Investor Presentation (March 2023)
49 slides from BioHarvest Sciences's investor presentation, March 2023
Slide 1: Corporate Presentation March 2023
CORPORATE PRESENTATION MARCH 2023
Slide 2: Forward-looking information disclaimer
The following presentation contains future looking information based on management expectations. Viewers are cautioned that future looking information is subject to risks and uncertainties including the risk that the company will not achieve its production and sales targets as anticipated or that pr
Slide 3: At the cutting edge intersection of health, technology and sustainability
at . a : ATTHE CUTTING EDGE ./ a INTERSECTION OF / * v/ i HEALTH & > WELLNESS ~~ | TECHNOLOGY & SUSTAINABILITY ~ x va
Slide 4: Global Leader in Plant Cell Biology
GLOBAL LEADER IN PLANT CELL BIOLOGY
Slide 5: Corporate Presentation
CORPORATE PRESENTATION MARCH 2023 CSE: BHSC OTCQB: CNVCF FRANKFURT: 8MV
Slide 6: Mother Nature provides active medicinal compounds inefficiently
MOTHER NATURE PROVIDES ACTIVE MEDICINAL COMPOUNDS Resveratrol BUT Verbascoside Alkaloids MOTHER NATURE PROVIDES THEM INEFFICIENTLY & Flavonoids TECHNOLOGY HAS FAILED TO DELIVER Gossypol Polyphenols INCONSISTENT UNCLEAN HIGH COST DAMAGES THE ENVIRONMENT
Slide 7: Industrial scale platform
OUR BIO-PLANT CELLICITATION TECHNOLOGY IS THE ONLY INDUSTRIAL SCALE PLATFORM 100% CONSISTENCY THAT BRINGS PATENTABLE PLANT BASED THERAPEUTIC SOLUTIONS WHICH: OUR ASEPTIC FIVE • MAINTAIN THE ORIGINAL NATURAL COMPOUND CLEANLINESS C’S LOW COST STRUCTURE (NON-GMO) • ARE FULL SPECTRUM • IS CONSISTENT & R
Slide 8: Delivered on 2022 guidance; 2023 revenue guidance $17-$20 million
DELIVERED ON 2022 GUIDANCE AND PROVIDED 2023 REVENUE GUIDANCE OF $17-$20 MILLION $17-20m $10m $9m $7m $6m $5.6m $5m $4m $3m $2.1m $2m $1m $0.4m $- 2020 2021 2022 2023
Slide 9: Consistent growth across USA and Israel markets with one product
CONSISTENT STELLAR GROWTH ACROSS USA AND ISRAEL MARKETS WITH ONE PRODUCT (2 SKU’S) CONSISTENT SALES AND MARKETING CHANNELS IN USA AND ISRAEL This will increase as retention strategies and product market fit matures.
Slide 10: Botanical-Sphere strategic vision
DEFINED A CLEAR STRATEGIC VISION TO DELIVER OUR ASPIRATION OF BUILDING A MULTI-BILLION $ BIOTECH COMPANY BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals F&B Pharmaceutical D2C/B2B API & Companies Adjuvants Polyphenols/ Anti-oxidants Mental Health Rx FDA Olive Cells + Hea
Slide 11: Botanical-Sphere
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals F&B Pharmaceutical D2C/B2B API & Companies Adjuvants Polyphenols/ Anti-oxidants Mental Health Rx FDA Olive Cells + Health authorities worldwide D2D Red Grape Cells Eye Health Rx Research Physicians Institutions Pomegranate
Slide 12: Botanical-Sphere: plant cell biology
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE PLANT CELL BIOLOGY
Slide 13: Botanical synthesis versus chemical and bio-synthesis
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE CHEMICA L BIO- SYNTHESIS BOTA NICA L SYNTHESIS SYNTHESIS SYNTHESIS ARTIFICIAL REPRODUCIBLE AND GMO MULTI- STEP, ENZYME- NON GMO REPRODUCIBLE AND RELIABLE EXECUTION OF CHEMICAL CATALYZED REPRODUCIBLE PROCESS RELIABLE PROCESS OF COMBINING REACTIONS TO OBTA
Slide 14: Bio-Plant CELLicitation platform technology
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE TM BIO PLANT CELLICITATION PLATFORM TECHNOLOGY ONE TIME THE CELL CELL PROCCESS PLANT ISOLATION BANK PREPETUAL CELL HARVESTING PROPAGATION PRODUCTION DRYING PROCCESS BANK WET CELLS UPSTREAM DOWNSTREAM Patients Bio-Plant CELLicitation Platform Technology B
Slide 15: Red grape, olive and pomegranate cells
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Red Grapes Cells Olives Cells Pomegranate Cells BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-oxidants, Psychedelics, Proteins, etc… Patients Bio-Plant CELLicitation Platform Technology Botanical Synthesis PLANT CELL
Slide 16: Botanical compositions and clinical studies
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Physicians Clinical Studies BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-oxidants, Psychedelics, Proteins, etc… Bio-Plant CELLicitation Platform Technology Botanical Synthesis PLANT CELL BIOLOGY
Slide 17: FDA and health authorities
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE FDA + Health authorities worldwide Physicians Clinical Studies BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-oxidants, Psychedelics, Proteins, etc… Bio-Plant CELLicitation Platform Technology Botanical Synthesis PLANT
Slide 18: Nutraceutical channels
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals F&B D2C/B2B Polyphenols/ Anti-oxidants FDA Olive Cells + Health authorities worldwide D2D Red Grape Cells Physicians Pomegranate Cells Clinical Studies D2C BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-
Slide 19: Nutraceutical channels and consumers
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals F&B D2C/B2B Polyphenols/ Anti-oxidants FDA Olive Cells + Health authorities worldwide D2D Red Grape Cells Physicians Pomegranate Cells Clinical Studies D2C BOTANICAL COMPOSITIONS Development & Industrial Scale Production Polyphenols, Anti-
Slide 20: Size of prize for VINIA and other polyphenols is enormous
SIZE OF PRIZE FOR VINIA & OTHER POLYPHENOLS IS ENORMOUS CURRENTLY WE PLAY IN APPROX 13% OF REVENUE POOLS. DIETARY SUPPLEMENT SOURCE: PERSISTENCE MARKET RESEARCH 2020 DIETARY SUPPLEMENT REPORT US MARKET SIZE: PROFIT MARGIN $8 Billion $$$$ with CAGR 8%* * PERSISTENCE RESEARCH DEITARY MARKET REPORT 202
Slide 21: VINIA polyphenols and piceid resveratrol
Slide 22: VINIA is the first demonstration of CELLicitation technology
VINIA (BASED ON RED GRAPE CELLS) IS THE FIRST DEMONSTRATION OF THE POWER OF OUR CELLICITATION TECHNOLOGY Heart health Blood pressure Supports heart health by improving Supports blood pressure already blood flow and delivery of oxygen.* within normal range Increases dilation of arteries and blood ves
Slide 23: Brand and product strategy: blood flow market leader
BRAND & PRODUCT STRATEGY BLOOD FLOW MARKET LEADER CLINICAL PROOF - WE ARE THE BEST IN THE MARKET Optimize messaging, landing pages, SEO, advertising. Build this across D2C, Amazon, and D2D
Slide 24: Brand and product strategy: educational content
BRAND & PRODUCT STRATEGY EDUCATIONAL CONTENT REAL SCIENCE SHOWN IN EDUCATIONAL AND VISUAL WAYS Teaching people what's happening in their bodies, even if they don't notice an experience. Most supplement companies don't have the science and understanding to build this content. The Science Behind VINIA
Slide 25: Social proof in USA continues to grow (1870+ reviews)
SOCIAL PROOF IN USA CONTINUES TO GROW EXPONENTIALLY (1870+ REVIEWS) - BUILDING SIGNIFICANT CREDIBILITY FOR THE VINIA BRAND March 9th, 2023 OCT 25th, 2022 JUL 4, 2022 APR 4, 2022 OCT 14, 2021
Slide 26: Significant expansion planned in next 6-12 months
SIGNIFICANT EXPANSION PLANNED IN NEXT 6-12 MONTHS H2, 2023 H1, 2025 CAN 5% UK+EU +6% H1, 2025 JP 9% USA 35% H1, 2023 CH, PH SK 27% CHINA – CROSS BORDER 2023 AND 2024 LOCAL SALES - 2025 Source: Persistence Market Research 2020 Dietary Supplement Report and iimedia for China Market
Slide 27: Botanical-Sphere
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals F&B Pharmaceutical D2C/B2B API & Companies Adjuvants Polyphenols/ Anti-oxidants Mental Health Rx FDA Olive Cells + Health authorities worldwide Physicians Physicians D2D Red Grape Cells Eye Health Rx Research Institutions P
Slide 28: Direct to Doctors program targeting 45,000 practitioners
DIRECT TO DOCTORS (D2D) PROGRAM IS TARGETING 45,000 “PRACTITIONERS” IN THE US INCLUDES DOCTORS, NURSES, “HEALTH COACHES,” CHIROPRACTORS, NUTRITIONISTS, PHYSICAL THERAPISTS, PREVENTION-FOCUSED AND SUPPORTERS OF SUPPLEMENTS & NUTRACEUTICALS
Slide 29: Marketing initiatives supporting the D2D push
SPECIFIC MARKETING INITIATIVES IN PLACE TO SUPPORT OUR D2D PUSH Dr Brian Cornblatt Chief Medical Officer PODCAST TOUR FOR PARTICIPATING IN KEY SUPPORT D2D WITH KEY DR BRIAN EVENTS PARTNERS
Slide 30: Early success with major strategic customers
WE HAVE ALREADY HAD GREAT EARLY SUCCESS WITH MAJOR STRATEGIC CUSTOMERS
Slide 31: Botanical-Sphere
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals F&B Pharmaceutical F&B Companies D2C/B2B API & Adjuvants Polyphenols/ Anti-oxidants Mental Health Rx FDA Olive Cells + Health authorities worldwide Eye Health Rx Research Physicians Physicians Red Grape Cells Institutions P
Slide 32: Disrupting the protein bar market
DISRUPTING THE PROTEIN BAR MARKET PROFIT MARGIN PROTEIN+ BAR $$$ US MARKET SIZE: $3 Billion with CAGR 6%* FOR ILLUSTRATION PURPOSE ONLY * POLARIS PROTEIN BAR MARKET RESEARCH REPORT 2022-2030
Slide 33: Only dietary supplement protein bar with functional health claims
CATEGORY DISRUPTOR - WE WILL BE THE ONLY DIETARY SUPPLEMENT PROTEIN BAR AVAILABLE DIRECT TO CONSUMERS WHICH HAS FUNCTIONAL HEALTH CLAIMS Calories 210 Calories 230 Protein 15 g Protein 14 g Net Carbs 13 g Fat 10 g Fat 9g Fiber 10 g KEY CLAIMS Fiber 3+ g Sugar 5g Sugar 7g Improves physical energy and
Slide 34: Disrupting and premiumizing the coffee market
DISRUPTING & PREMIUMIZING THE COFFEE MARKET WITH SCIENCE DRIVEN FUNCTIONALITY BACKED BY CLINICAL TRIALS US DECAF COFFEE MARKET US MARKET SIZE: $4 Billion PROFIT MARGIN with CAGR >5%* $$$ FOR ILLUSTRATION PURPOSE ONLY `SOURCE: MARKETUS RESEARCH 20 MILLION* 20% FROM TRANSPARENCY MARKET RESEARCH REPORT
Slide 35: Size of decaf prize is significant
SIZE OF DECAF PRIZE IS SIGNIFICANT Whereas 18% of respondents only drink decaf.
Slide 36: Only decaf coffee backed by science with sustained energy
THE ONLY DECAF COFFEE BACKED BY SCIENCE WITH THE ABILITY TO PROVIDE SUSTAINED ENERGY VIA INCREASE IN BLOOD FLOW KEY CLAIMS Improves physical energy and mental alertness via the delivery of increased blood flow, oxygen and nutrients to your brain, heart and body 12 HOUR SUSTAINED RELEASE $29.99 $28.0
Slide 37: Similar potential with olive and pomegranate cells
SIMILAR POTENTIAL WITH OLIVE CELLS & POMEGRANATE CELLS ACROSS NUTRACEUTICAL & PHARMA PROFIT PILLARS FOR ILLUSTRATION PURPOSE ONLY TRADEMARKS ARE PLACEhOLDERS Q1-2024 Q1-2025
Slide 38: Botanical-Sphere
BIOHARVEST HEALTH & WELLNESS BOTANICAL-SPHERE Nutraceuticals Pharmaceuticals Pharmaceutical Pharmaceutical F&B D2C/B2B API & Companies Companies Adjuvants Cannabinoids Mental Health Rx FDA + Polyphenols Health authorities worldwide Physicians Eye Health Rx Research Physicians Institutions Olive Cell
Slide 39: Key indications: eye health
CONDUCT CLINICAL TRIALS FOR OUR BOTANICAL COMPOSITIONS AS APIs FOR DRUG DEVELOPMENT AND LEVERAGE FINDINGS FOR POTENTIAL DIETARY SUPPLEMENT DEVELOPMENT KEY INDICATIONS EYE HEALTH OPTIC NEURITIS CARDIOVASCULAR HEALTH RAYNAUD’S DISEASE RED GRAPE CELLS POWDER BRAIN HEALTH ALZHEIMER’S, DEMENTIA SKIN HEAL
Slide 40: Key indications: eye health
KEY INDICATIONS EYE HEALTH OPTIC NEURITIS CARDIOVASCULAR HEALTH RAYNAUD’S DISEASE RED GRAPE CELLS POWDER BRAIN HEALTH ALZHEIMER’S, DEMENTIA SKIN HEALTH ECTOPIC DERMATITIS, ECZEMA, PSORIASIS
Slide 41: Key indications: cardiovascular
CONDUCT CLINICAL TRIALS FOR OUR BOTANICAL COMPOSITIONS AS APIs FOR DRUG DEVELOPMENT AND LEVERAGE FINDINGS FOR DIETARY SUPPLEMENT DEVELOPMENT KEY INDICATIONS EYE HEALTH OPTIC NEUROTICS CARDIOVASCULAR RAYNAUD’S DISEASE RED GRAPE CELLS POWDER BRAIN HEALTH ALZHEIMER’S, DEMENTIA SKIN HEALTH ECTOPIC DERMA
Slide 42: Key indications: brain health
CONDUCT CLINICAL TRIALS FOR OUR BOTANICAL COMPOSITIONS AS APIs FOR DRUG DEVELOPMENT AND LEVERAGE FINDINGS FOR DIETARY SUPPLEMENT DEVELOPMENT KEY INDICATIONS EYE HEALTH OPTIC NEUROTICS CARDIOVASCULAR HEALTH RAYNAUD’S DISEASE RED GRAPE CELLS POWDER BRAIN HEALTH ALZHEIMER’S, DEMENTIA SKIN HEALTH ECTOPI
Slide 43: Key indications: skin health
CONDUCT CLINICAL TRIALS FOR OUR BOTANICAL COMPOSITIONS AS API’S FOR DRUG DEVELOPMENT AND LEVERAGE FINDINGS FOR DIETARY SUPPLEMENT DEVELOPMENT KEY INDICATIONS EYE HEALTH OPTIC NEUROTICS CARDIOVASCULAR HEALTH RAYNAUD’S DISEASE RED GRAPE CELLS POWDER BRAIN HEALTH ALZHEIMER’S, DEMENTIA SKIN HEALTH ECTOP
Slide 44: Wins Sustainability Leadership Award
BioHarvest Sciences WINS The Business Intelligence Group 2022 Sustainability Leadership Award ״Byfraction delivering the benefits of plants using a of the energy, water, and land that agriculture would, we see the potential for conserving valuable globbal resources at the game-changing scale ״ A
Slide 45: Led by a high-performance experienced management team
LED BY A HIGH-PERFORMANCE EXPERIENCED MANAGEMENT TEAM Ilan Sobel DR. Yochi Hagay DR. Malkit Azachi Michal Sapir Dr. Brian Cornblatt CEO CTO VP R&D VP Regulation Affairs Chief Med Officer Justin Meiklem Alan Rootenberg Kobi Rosenzweig Jarred Turner Head of IR CFO VP Operations VP of E-Commerce
Slide 46: Supported by a team of industry leaders
SUPPORTED BY A TEAM OF INDUSTRY LEADERS SCIENTIFIC ADVISORY BOARD Gavriel Lambert STEVEN LEHRER DR RHONA APPLEBAUM DR. DENNIS GOODMAN DR. GEORGE GARIBALDI INVESTMENT BANKING VETERAN BIOTECH LEADER REGULATORY AND SCIENTIFIC AFFAIRS CARDIOLOGIST Psychiatrist & Neuro-Scientist SCOTT MCCUNE COL CHRIS HA
Slide 47: Take the power of our technology to new frontiers
TAKE THE POWER OF OUR TECHNOLOGY TO NEW FRONTIERS Produce primary metabolites such as Produce antioxidant compounds that can Assess the health impact of 1 premium proteins that are needed to provide required nutrition for humans to live in 2 help reduce human cellular stress and prevent damage cause
Slide 48: Key highlights
KEY HIGHLIGHTS: Global leader in Plant Cell Biology Innovative and disruptive Biotech Platform Technology opening the gate for patentable Botanical Drugs Validated and proven technology across multiple verticals with significant current revenues High scalability with low capex requirements ($3-4M) a
Slide 49: Bringing the power of the plant kingdom to the people
PURPOSE DRIVEN COMPANY BRINGING THE POWER OF THE PLANT KINGDOM TO THE PEOPLE
BioHarvest Sciences — Investor Presentation (March 2023) on 6ix